原发性硬化性胆管炎的诊断和治疗

舒慧君; 朱峰

原发性硬化性胆管炎的诊断和治疗

舒慧君,
朱峰

中国医学科学院北京协和医院消化内科

详细信息

中图分类号: R575.6
计量
- 文章访问数: 3539
- HTML全文浏览量: 8
- PDF下载量: 918
- 被引次数: 0
出版历程
- 收稿日期: 2011-02-14
- 出版日期: 2011-06-20

Diagnosis and treatment of primary sclerosing cholangitis

摘要

摘要: 原发性硬化性胆管炎(PSC)是一种以胆管的进行性炎症、纤维化和多发性狭窄为主要病理特征的慢性胆汁淤积性肝病,其发病可能与遗传及免疫机制有关,其病变范围可累及肝内和肝外胆管。部分患者具备典型的胆汁淤积表现和PSC的组织学特征,但胆管造影正常,称为小胆管PSC。PSC的病程多呈慢性进行性,最终演变为终末期肝病。60%～80%的PSC患者可并发炎症性肠病,约20%的患者还可并发胆管癌。目前针对PSC的治疗,除肝移植外尚无确切有效的治疗方法。
- 胆管炎 /
- 硬化性
Abstract: Primary sclerosing cholangitis (PSC) is a chronic, cholestatic liver disease characterized by inflammation and fibrosis of both intra-and extra-hepatic bile ducts, leading to the formation of multifocal bile duct strictures and eventually cirrhosis and end-stage liver disease.Genetic and immunologic factors appear to play key roles in disease susceptibility and progression.Patients with histological, biological and clinical features of PSC but with normal cholangiogram are diagnosed as small duct PSC.PSC is strongly associated with inflammatory bowel disease (IBD) and cholangiocarcinoma.The reported frequency of IBD and cholangiocarcinoma in patients with PSC is 60%-80% and 20% respectively.Except for liver transplantation, no specific therapy has been proved effective for PSC.
- cholangitis /
- sclerosing

HTML全文

参考文献(31)

[1]Bjrnsson E, Olsson R, Bergquist A, et al.The natural history ofsmall-duct primary sclerosing cholangitis[J].Gastroenterology, 2008, 134 (4) :975-980.

[2]Jayaram H, Satsangi J, Chapman RW.Increased colorectal neoplasiain chronic ulcerative colitis complicated by primary sclerosingcholangitis:fact or fiction[J].Gut, 2001, 48 (3) :430-434.

[3]Fevery J, Verslype C.An update on cholangiocarcinomaassociated with primary sclerosing cholangitis[J].Curr OpinGastroenterol, 2010, 26 (3) :236-245.

[4]Kaplan GG, Laupiand KB, Butzner D, et al.The burden of largeand small duct primary sclerosing cholangitis in adults andchildren:a population-based analysis[J].Am J Gastroenterol, 2007, 102 (5) :1042-1049.

[5]Kingham JG, Kochar N, Gravenor MB.Incidence, clinicalpatterns, and outcomes of primary sclerosing cholangitis inSouth Wales, United Kingdom[J].Gastroenterology, 2004, 126 (7) :1929-1930.

[6]Bambha K, Kim WR, Talwalkar J, et al.Incidence, clinical speclrum, and outcomes of primary sclerosing cholangitis in a United Statescommunity[J].Gastroenterology, 2003, 125 (5) :1364-1369.

[7]Chapman R, Fevery J, Kalloo A, et al.Diagnosis and managementof primary sclerosing cholangitis[J].Hepatology, 2010, 51 (2) :660-678.

[8]Kaplan GG, Laupland KB, Butzner D, et al.The burden of largeand small duct primary sclerosing cholangitis in adults andchildren:a population-based analysis[J].Am J Gastroen terol, 2007, 102 (5) :1042-1049.

[9]Cooper JF, Brand EJ.Symptomatic sclerosing cholangitis inpatients with a normal alkaline phosphatase:two case reportsand a review of the literature[J].Am J Gastroenterol, 1988, 83 (3) :308-311.

[10]Boberg KM, Fausa O, Haaland T, et al.Features of autoimmunehepatitis in primary sclerosing cholangitis:an evaluation of 114primary sclerosing cholangitis patients according to a scoringsystem for the diagnosis of autoimmune hepatitis[J].Hepatoloty, 1996, 23 (6) :1369-1376.

[11]Bangarulingam SY, Gossard AA, Petersen BT, et al.Complicationsof endoscopic retrograde cholangiopancreatography in primarysclerosing cholangitis[J].Am J Gastroenterol, 2009, 104 (4) :855-860.

[12]Berstad AE, Aabakken L, Smith HJ, et al.Diagnosticaccuracy of magnetic resonance and endoscopic retrogradecholangiography in primary sclerosing cholangitis[J].ClinGastroenterol Hepatol, 2006, 4 (4) :514-520.

[13]Angulo P, Pearce DH, Johnson CD, et al.Magnetic resonancecholangiography in patients with biliary disease:its role in primarysclerosing cholangitis[J].J Hepatol, 2000, 33 (4) :520-527.

[14]Etzel JP, Eng SC, Ko CW, et al.Complications after ERCP inpatients with primary sclerosing cholangitis[J].GastrointestEndosc, 2008, 67 (4) :643-648.

[15]Feldman M, Friedman LS, Brandt LJ.Sleisenger and Fordtran'sgastrointestinal and liver disease[M].9th ed.Philadelphia (Pa) :WB Saunders, 2010:1153-1166.

[16]Burak KW, Angulo P, Lindor KD.Is there a role for liver biopsyin primary sclerosing cholangitis[J].Am J Gastroenterol, 2003, 98 (5) :1155-1158.

[17]Floreani A, Rizzotto ER, Ferrara F, et al.Clinical courseand outcome of autoimmune hepatitis/primary sclerosingcholangitis ovedap syndrome[J].Am J Gastroenterol, 2005, 100 (7) :1516-1522.

[18]Webster GJ, Pereira SP, Chapman RW.Autoimmunepancreatitis/IgG4-associated cholangitis and primarysclerosing cholangitis--overlapping or separate diseases[J].J Hepatol, 2009, 51 (2) :398-402.

[19]Kamisawa T, Takuma K, Anjiki H, et al.Sclerosing cholangitisassociated with autoimmune pancreatitis differs from primary sclerosingcholangitis[J].World J Gastroenterol, 2009, 15 (19) :2357-2360.

[20]Deshpande V, Sainani NI, Chung R, et al.IgG4-associatedcholangitis:a comparative histological and immunophenotypicstudy with primary sclerosing cholangitis on liver biopsymaterial[J].Mod Pathol, 2009, 22 (10) :1287-1295.

[21]Loftus EV Jr, Harewood GC, Loftus CG, et al.PSC-IBD:aunique form of inflammatory bowel disease associated withprimary sclerosing cholangitis[J].Gut, 2005, 54 (1) :91-96.

[22]Rasmussen HH, Fallingborg JF, Mortensen PB, et al.Hepatobiliary dysfunction and primary sclerosing cholangitis inpatients with Crohn's disease[J].Scand J Gastroenterol, 1997, 32 (6) :604-610.

[23]Chapman R, Fevery J, Kalloo A, et al.Diagnosis andmanagement of primary sclerosing cholangitis[J].Hepatology, 2010, 51 (2) :660-678.

[24]Soetikno RM, Lin OS, Heidenreich PA, et al.Increased risk ofcolorectal neoplasia in patients with primary sclerosing cholangitisand ulcerative colitis:a meta-analysis[J].Gastrointest Endosc, 2002, 56 (1) :48-54.

[25]Lindor KD, Enders FB, Schmoll JA, et al.Randomized, double-blind controlled trial of high-dose ursodeoxycholic acid forprimary sclerosing cholangitis[Abstract][J].Hepatology, 2008, 48 (Suppl 1) :378A.

[26]Gluck M, Cantone NR, Brandabur JJ, et al.A twenty-year experiencewith endoscopic therapy for symptomatic primary sclerosingcholangitis[J].J Clin Gastroenterol, 2008, 42 (9) :1032-1039.

[27]Baluyut AR, Sherman S, Lehman GA, et al.Impact of endoscopictherapy on the survival of patients with primary sclerosingcholangitis[J].Gastrointest Endosc, 2001, 53 (3) :308-312.

[28]Stiehl A, Rudolph G, Klters-Plachky P, et al.Development ofdominant bile duct stenoses in patients with primary sclerosingcholangitis treated with ursodeoxycholic acid:outcome afterendoscopic treatment[J].J Hepatol, 2002, 36 (2) :151-156.

[29]Campsen J, Zimmerman MA, Trotter JF, et al.Clinically recurrentprimary sclerosing cholangitis following liver transplantation:atime course[J].Liver Transpl, 2008, 14:181-185.

[30]Alabraba E, Nightingale P, Gunson B, et al.A re-evaluation of therisk factors for the recurrence of primary sclerosing cholangitis inliver allografts[J].Liver Transpl, 2009, 15 (3) :330-340.

[31]Kim WR, Poterucha JJ, Wiesner RH, et al.The relative role of theChild-Pugh classification and the Mayo natural history modelin the assessment of survival in patients with primary sclerosingcholangitis[J].Hepatology, 1999, 29 (6) :1643-1648.

施引文献

资源附件(0)

访问统计